top of page

Big Pharma commercial expertise  |  Delivered as expansion strategy

STRATEGIC ADVISORY FOR RARE-DISEASE AND SPECIALTY BIOPHARMA ON EXPANSION BEYOND THE US AND EU5 AND REACHING HIGH-VALUE GROWTH MARKETS WITHOUT DISTRACTING INTERNAL TEAMS OR ADDING LOCAL INFRASTRUCTURE    
|     Explore how Gradus V extends your asset's reach

PROBLEM

Breakthrough Science. Constrained Commercial Reach.

 

The most innovative therapies increasingly originate in emerging and growth-stage biopharma - the originators of 85% of the novel medicines launched globally in 2024, according to the IQVIA Institute, and a rising share year over year. These are organizations designed to advance pipeline science, not to manage heavy international administrative operations. Approval commands your capital; the primary launch commands 100% of your focus. Markets beyond the US and EU5 remain, for now, out of reach. It is a structural gap, not a strategic one - and it leaves significant value unrealized.

​

  • The Bandwidth Constraint: Primary FDA/EMA launches rightly command headquarters' full focus, leaving little internal capacity to evaluate or plan for what lies beyond.

  • The Pricing Trap: Entering expansion markets without a coordinated, macro-level access strategy can trigger cross-border International Reference Pricing (IRP) mechanisms, retroactively eroding core US/EU5 margins.

  • The Market Visibility Gap: Local government funding structures, complex patient pathways, specialist KOL networks, and regional partner ecosystems are inherently opaque from the outside.

 

If this describes your launch reality, the gap is addressable - without adding a single internal hire.

OPPORTUNITY

Second Patient Population, Comparable in Scale.

 

Beyond the highly saturated US and EU5, select mature international markets have evolved: established treatment infrastructure, dedicated state funding pathways, and partner ecosystems ready to activate. Reaching them no longer requires local corporate weight - it requires the commercial strategy to navigate them.

​

  • 670M: Combined US and EU5 population, where most launch strategies conclude.

  • 500M+: Additional population across select mature expansion markets beyond the US and EU5. Funded. Equipped. Ready.

  • $4.7B+ in Accessible Public Funding: Dedicated government funding pathways specifically allocated for innovative therapies exist and are fully accessible across select mature expansion territories.

  • Mature Clinical Infrastructure: Established rare disease registries, testing networks, and key centers of excellence are fully operational and prepared to integrate breakthrough assets.

 

The infrastructure and funding exists. What is required is the strategy to connect your asset to both.

SOLUTIONS

Structured Expansion Architecture

Gradus V acts strictly as your external strategic and vetting advisory engine  |  We translate fragmented market parameters into highly disciplined commercial decisions before you commit capital

​​

​

​

THE GRADUS V 5-STEP SOLUTION

01

IDENTIFY    |    AI Scouting & Analytics

AI-powered analytics transform fragmented market data into clear commercial intelligence. We assess commercial potential, pricing dynamics, and launch barriers across selected markets - giving you evidence-based go/no-go decisions before committing resources

02

MAP    |    Agentic AI Workflows

​

Agentic AI workflows scan partner landscapes, asset ecosystems, and stakeholder networks in real time. We surface what is invisible from HQ - local partners, KOL networks, funding pathways, competitive dynamics - structured into actionable intelligence

03

​CONNECT    |    Alliance Forging

We help to strategically identify the right local partners - curated, qualified relationships across select mature expansion markets. Aligned to your commercialization pathway and pricing strategy. No cold databases

04

BUILD    |    Launch Excellence

We design your launch architecture end-to-end: market access, pricing and reimbursement pathway, GTM readiness, and launch governance. Built to Big Pharma standard - scaled to your operating model

SCALE    |    Strategic Coordination

Full expansion package: Intelligence, partners identification, launch architecture, and cross-market sequencing - delivered as a single integrated engagement. One team. One framework. Multiple markets

05

The Operating Model

 

We design the regulatory and access blueprint, map the local networks, identify and assess the partners. Your chosen local commercial partner executes on the ground. Your internal team remains 100% focused on core markets and science.

 

Engagements begin with a focused strategic assessment - structured, time-bound, and decision-ready.

IMPACT

Selected Strategic Engagements Across Launch Strategy and Excellence

Global Innovative Pharma  |  First-In-Class Pediatric Gene Therapy  |  ~$280B Market Cap

​

  • The Barrier: A first-in-class pediatric gene therapy presented to select growth regions with zero local newborn screening infrastructure, immature clinical pathways, and no existing state reimbursement pathways.

  • The Strategy: Engineered an innovative outcomes-based access model, structured the formal state regulatory pathway, and mapped out a scalable, nation-wide newborn screening network.

  • The Impact: 280+ newborns identified annually. State-funding pathways secured. Region established as the asset's second-largest global market after the US.

Rare Disease Biotech  |  Ultra-Rare Portfolio Mapping   |~$2B Market Cap

​

  • The Barrier: Zero internal commercial team bandwidth or infrastructure within a rapid-growth biotech to analyze, model, or value commercial expansion opportunities across secondary international territories.

  • The Strategy: Formulated risk-insulated commercial entry strategies, completed comprehensive multi-market stakeholder mapping, and evaluated local ATMP clinical delivery frameworks.

  • The Impact: 57 patients identified. $145M in annual public funding pathways mapped across expansion markets. Zero local corporate overhead added.

International Specialty Pharma  |  Enterprise Launch Excellence  |  $10B+ Market Cap

​

  • The Barrier: Escalating operational complexity across a scaling specialty portfolio demanded a uniform, rigorous framework to align regional launch management.

  • The Strategy: Developed an enterprise-wide Global Launch Excellence framework encompassing standardized asset archetyping, readiness reviews, and cross-market launch sequencing.

  • The Impact: A repeatable, highly disciplined, and corporate-scalable launch operating blueprint built for long-term clinical commercialization.

Clinical-Stage Biotech — Pre-Commercial Corridor Protection

​

  • The Barrier: Early access requests from non-core patient markets threatened to inadvertently trigger IRP reference mechanisms, exposing and risking global launch margins.

  • The Strategy: Engineered a legally insulated, reversible pre-commercialization access framework protecting global intellectual property and target pricing corridors.

  • The Impact: Early patient market access successfully enabled while maintaining absolute integrity of core global launch pricing corridors.

Each engagement began the same way: a structural gap, addressed without diverting a single internal resource.

ABOUT

Specialized in Rare Disease  |  Focused Where Expansion is Hardest

Gradus V brings commercialization, launch, and expansion expertise across the therapy areas and geographies where generalist advice falls short - built by senior commercial leaders from Fortune 500 pharmaceutical organizations, now dedicated entirely to expansion. Our strategic advisory methodology combines real-world operations leadership with executive foundations from INSEAD and Stanford University.

  • Therapy Areas: Oncology & Hematology · Neurology · Ophthalmology · Metabolic & Lysosomal Disorders
     

  • Product Modalities: Small Molecules · Biologics · Advanced Therapies (ATMPs) · Medical Devices & Diagnostics
     

  • Cumulative Expertise: 40+ years of cumulative Big Pharma commercial leadership, 50+ blockbuster product launches across developed and emerging regions, 39 markets covered through operations leadership, and commercial scales managed from $350M to $1B over 15 years

Gradus V — strategic advisory for rare-disease and specialty biopharma expanding beyond core US and EU5 markets. Begin the conversation.
PARTNERS
bottom of page